ClinicalTrials.gg
RecruitingNCT07270263HEM-DOACUpdated Dec 26, 2025

Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies

An interventional study of Apixaban and Rivaroxaban in Lymphoma, Leukemia and Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, sponsored by Medical University of Gdansk. Recruiting at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-26.

Sponsored by Medical University of Gdansk · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 6 months ago, but the record still lists the study as recruiting.
  • Registered 1 year after the study started (first participant enrolled Nov 2024, registered Nov 2025).
  • Started Nov 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 73 studies in Lymphoma with a site in Poland — 6 open to participants now, 21 under way, 10 of them phase 3. Lymphoma · Poland.

Planned enrollment
48th of 72
100 · median 140
Started
2024
with 3 others
No phase
6 of 73
1 open now
Primary completion
2026-04
later than 7 of 20 live
Registered
73rd of 73
by date

Among the 73 studies in Lymphoma with a site in Poland, this one is the 48th largest by planned enrollment of the 72 interventional ones that give a count, is one of 4 that started in 2024, is one of 6 with no phase, reaches primary completion later than 7 of the 20 other live ones, and was the 73rd registered.

Lymphoma

3,020 studies on the registry are indexed under Lymphoma; 434 are open to participants now.

Browse Lymphoma studies →

Open to participants now

6 of the 73 studies in Lymphoma with a site in Poland are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Lymphoma with a site in Poland, or all of them as a file.
02

Study summary

This study investigates the efficacy and safety of direct oral anticoagulants (DOACs) in comparison with standard low-molecular-weight heparin (LMWH) for the prevention of venous thromboembolism in patients with hematological malignancies. Eligible participants will be randomized to receive reduced-dose apixaban, reduced-dose rivaroxaban, or standard-dose LMWH. The primary objective is to evaluate the incidence of venous thromboembolism during a 6-month follow-up period. Secondary objectives include assessment of bleeding complications, overall survival, and treatment adherence. The results of this study may provide evidence for safer and more convenient thromboprophylaxis strategies in patients with blood cancers.

Read the detailed description

Patients with hematologic malignancies are at high risk of developing venous thromboembolism (VTE). Low-molecular-weight heparin (LMWH) is currently the standard of care for thromboprophylaxis in this population; however, daily subcutaneous administration is burdensome and may impair adherence. Direct oral anticoagulants (DOACs), such as apixaban and rivaroxaban, have demonstrated efficacy in the prevention and treatment of VTE in patients with solid tumors, but data in hematologic malignancies are limited.

This study is designed as a prospective, randomized, open-label, parallel-group trial to compare the efficacy and safety of reduced-dose apixaban and rivaroxaban with standard-dose LMWH in patients with hematologic malignancies requiring primary thromboprophylaxis.

Approximately 100 patients will be randomized in a 1:1:1 ratio to receive:

Apixaban 2.5 mg orally twice daily, Rivaroxaban 10 mg orally once daily, or LMWH (enoxaparin 40 mg subcutaneously once daily or equivalent). The primary endpoint is the incidence of symptomatic or objectively confirmed VTE within 6 months of randomization. Secondary endpoints include major and clinically relevant non-major bleeding events (as defined by ISTH), treatment adherence, and overall survival at 6 months.

This study aims to address the unmet clinical need for optimized, patient-friendly thromboprophylaxis in hematologic malignancies and to provide high-quality data that may guide future clinical practice.

03

Conditions studied

  • Lymphoma
  • Leukemia
  • Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
  • Venous Thromboembolic Disease
  • VTE (Venous Thromboembolism)
  • PE - Pulmonary Embolism
  • Hematologic Malignacies

Keywords

  • Apixaban
  • Rivaroxaban
  • Low-Molecular-Weight Heparin
  • Venous Thromboembolism
  • Cancer-Associated Thrombosis
  • Hematologic Malignancies
  • Direct Oral Anticoagulants
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Active hematologic at the time of initiation of systemic therapy, including multiple myeloma, myeloproliferative neoplasm, lymphoma or other hematologic cancer with a Khorana score ≥ 2 points (intermediate or high risk of venous thromboembolism, VTE)
  • Use of anticoagulant agents for primary thromboprophylaxis, including direct oral anticoagulants (DOACs) at reduced doses (apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily) or low-molecular-weight heparin (LMWH) (enoxaparin 40 mg subcutaneously once daily).

Exclusion criteria

Exclusion Criteria:

  • Major bleeding within the last month (including gastrointestinal or intracranial bleeding).
  • Active major bleeding.
  • concentration \< 8 g/dL.
  • Thrombocytopenia with count \<30 × 10⁹/L.
  • performance status of 3 or 4.
  • Expected survival \<6 months.
  • History of mechanical heart valve or severe mitral stenosis.
  • Estimated (eGFR) \< 25 mL/min.
  • Hepatic impairment ( ≥ 3× or ≥ 2× upper limit of normal).
  • Acute coronary syndrome or ischemic stroke within the last 6 months.
  • Anticipated significant drug-drug interactions between DOACs and anticancer agents.
  • Known antiphospholipid syndrome (APS).
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    APIXABAN (reduced dose)

    Participants receive apixaban 2.5 mg orally twice daily for at least 6 months.

    Drug: Apixaban

  • Experimental
    RIVAROXABAN (reduced dose)

    Participants receive rivaroxaban 10 mg orally once daily for at least 6 months.

    Drug: Rivaroxaban

  • Active comparator
    Low-Molecular-Weight Heparin (LMWH)

    Participants receive low-molecular-weight heparin, 40 mg subcutaneously once daily for at least 6 months.

    Drug: low molecular weight heparin (enoxaparin sodium)

Interventions

  • Oral tablet, 2.5 mg twice daily, for at least 6 months.

    Also known as: Eliquis, Poltixa

  • Oral tablet, 10 mg once daily, for at least 6 months.

    Also known as: Xarelto, Mibrex, Zarixa

  • DrugHeparin, Low-Molecular-WeightStudies of Heparin, Low-Molecular-WeightHeparin, Low-Molecular-Weight pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subcutaneous injection, 40 mg once daily (or equivalent), for at least 6 months.

    Also known as: Clexane, Neoparin

06

What researchers measure

Primary outcomes

  1. Incidence of Venous Thromboembolism (VTE)

    Number of patients who develop symptomatic or incidental venous thromboembolism (deep vein thrombosis or pulmonary embolism) confirmed by objective imaging during the study treatment period.

    Time frame: 6 months from randomization

  2. Incidence of Major Bleeding (ISTH criteria)

    Number of patients experiencing major bleeding as defined by the International Society on Thrombosis and Haemostasis (ISTH).

    Time frame: 6 months from randomization

  3. Incidence of Clinically Relevant Non-Major Bleeding (CRNMB)

    Number of patients experiencing clinically relevant non-major bleeding (CRNMB) according to ISTH definition.

    Time frame: 6 months from randomization

Secondary outcomes

  1. Overall Survival

    Proportion of patients alive at 6 months after randomization.

    Time frame: 6 months

  2. Treatment Discontinuation Due to Adverse Events

    Number of patients who discontinued study drug due to adverse events, including bleeding and intolerance.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • Department of Haematology & Transplantology
    Gdansk, Pomeranian Voivodeship 80-152, Poland
    Recruiting
    • Agata Ogłoza-Puchowska, MD, Principle Investigator · Contacta.ogloza@gumed.edu.pl · +48 58 584 43 40
    • Ewa Lewicka, Professor · Contacte.lewicka@gumed.edu.pl
    • Agata Ogłoza-Puchowska, MD · Principal investigator
    • Ewa Lewicka, Professor · Sub investigator
    • Andrzej Mital, Professor · Sub investigator
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared because this is a non-commercial, single-center academic study with no external data sharing agreements in place.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Apr 2026, 17 months after the start.

Of 161 non-industry interventional studies with no phase under Lymphoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 87. This study's planned 17 months is below that.

Counting every sponsor, half of 170 studies reached it within 43 months; a quarter within 23 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2025
First posted
Dec 8, 2025
StartActual
Nov 22, 2024
Primary completionEst.
Apr 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Dec 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07270263
Responsible party
Sponsor
First posted
Dec 8, 2025
Start date
Nov 22, 2024
Primary completion
Apr 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Dec 26, 2025

Study contacts

Agata Ogłoza-Puchowska, MD
Contact
a.ogloza@gumed.edu.pl
+48 58 584 43 40
Ewa Lewicka, Professor
Contact
ewa.lewicka@gumed.edu.pl

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Apixaban · Rivaroxaban

Start the discussion